Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 6,693 shares of Phibro Animal Health stock in a transaction on Friday, January 30th. The stock was sold at an average price of $40.09, for a total transaction of $268,322.37. Following the sale, the chief executive officer directly owned 31,980 shares of the company's stock, valued at approximately $1,282,078.20. This trade represents a 17.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jack Bendheim also recently made the following trade(s):
- On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total value of $271,692.64.
- On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.55, for a total value of $50,079.25.
- On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total value of $552,372.84.
- On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
- On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
- On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total value of $147,975.03.
- On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total transaction of $304,456.32.
- On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total transaction of $8,554.08.
- On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
- On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total transaction of $235,429.36.
Phibro Animal Health Trading Up 4.4%
NASDAQ PAHC opened at $41.91 on Tuesday. The firm's fifty day moving average price is $39.85 and its 200 day moving average price is $37.96. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $46.42. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of 25.25, a price-to-earnings-growth ratio of 1.14 and a beta of 0.80.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The company had revenue of $363.89 million during the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, sell-side analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on PAHC shares. Weiss Ratings reissued a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 29th. Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Phibro Animal Health currently has an average rating of "Hold" and an average target price of $31.40.
Check Out Our Latest Stock Analysis on Phibro Animal Health
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Capricorn Fund Managers Ltd purchased a new position in shares of Phibro Animal Health during the third quarter valued at $10,233,000. Allspring Global Investments Holdings LLC purchased a new position in Phibro Animal Health during the 3rd quarter valued at about $8,931,000. Bailard Inc. acquired a new position in shares of Phibro Animal Health in the 2nd quarter valued at about $259,000. Squarepoint Ops LLC acquired a new position in shares of Phibro Animal Health in the 2nd quarter valued at about $813,000. Finally, G2 Investment Partners Management LLC purchased a new stake in shares of Phibro Animal Health in the second quarter worth approximately $1,405,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.
Phibro Animal Health Company Profile
(
Get Free Report)
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
